Castle Biosciences, Inc.

CSTLNASDAQHealthcare● Active

$20.12

$-0.89(-4.24%)

Market Cap$610238634

P/E Ratio—

52W High$44.28

52W Low$14.59

Avg Volume383K

Open$20.94

Beta1.02

Net Income Financials Revenue

Castle Biosciences, Inc. (CSTL) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CSTL · net income · updated Jun 8, 2026

Core profitability metrics

CSTL · net income · margin · TTM · CAGR

Net income was −$24.2M for FY2025 (fiscal year ending 2025-12-31), down 232.4% year-over-year. Net profit margin was -7.0%. Based on available data, Castle Biosciences, Inc. has been profitable since at least 2019.

FY2025 Net Income−$24.2M▼ -232.4% YoY

Trailing 12M (TTM)−$12.8Mtrailing 4 quarters sum

Net Profit Margin-7.0%−$24.2M ÷ $344.2M

YoY Change-232.4%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2019

▸ FMP /income-statement · Annual · CSTL net income history · CSTL profit margin

Annual net income data

CSTL · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$24.2M▼ 232.4%-7.0%$344.2M

FY2024$18.2M▲ +131.7%5.5%$332.1M

FY2023Loss−$57.5M▲ +14.4%-26.1%$219.8M

FY2022Loss−$67.1M▼ 114.6%-49.0%$137.0M

FY2021Loss−$31.3M▼ 204.3%-33.3%$94.1M

Net income vs peers (Healthcare)

CSTL vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Castle Biosciences, Inc.YOU

CSTL

−$24.2M-232.4%-7.0%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Castle Biosciences, Inc. (CSTL) reported net income of −$24.2M for FY2025 (fiscal year ending 2025-12-31), down 232.4% year-over-year. The net profit margin was -7.0% — meaning the company kept $-0.07 of every dollar of revenue as profit.

Based on available data, Castle Biosciences, Inc. has been profitable since at least 2019. Net income reached a peak of $18.2M in FY2024. Data available for 9 fiscal years.

Castle Biosciences, Inc.'s net profit margin was -7.0% for FY2025, based on the latest annual results.

Investors sometimes search for "Castle Biosciences, Inc. net worth" — the company's market capitalization is a separate figure from CSTL net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CSTL net income · 4 questions

Castle Biosciences, Inc. is not currently profitable on an annual basis. The company reported a net loss of $24.2M for FY2025.

is CSTL profitabledoes CSTL make a profitCSTL profitabilityCSTL profitable company

▸ Source: FMP /income-statement · GAAP · Castle Biosciences, Inc. · Castle Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026